Archives
- 2018-07
- 2019-08
- 2019-09
- 2019-10
- 2019-11
- 2019-12
- 2020-01
- 2020-02
- 2020-03
- 2020-04
- 2020-05
- 2020-06
- 2020-07
- 2020-08
- 2020-09
- 2020-10
- 2020-11
- 2020-12
- 2021-01
- 2021-02
- 2021-03
- 2021-04
- 2021-05
- 2021-06
- 2021-07
- 2021-08
- 2021-09
- 2021-10
- 2021-11
- 2021-12
- 2022-01
- 2022-02
- 2022-03
- 2022-04
- 2022-05
- 2022-06
- 2022-07
- 2022-08
- 2022-09
- 2022-10
- 2022-11
- 2022-12
- 2023-01
- 2023-02
- 2023-03
- 2023-04
- 2023-05
- 2023-06
- 2023-07
- 2023-08
- 2023-09
- 2023-10
- 2023-11
- 2023-12
- 2024-01
- 2024-02
- 2024-03
- 2024-04
- 2024-05
- 2024-06
- 2024-07
- 2024-08
- 2024-09
- 2024-10
- 2024-11
- 2024-12
- 2025-01
-
Recently Bristol Myers Squibb and
2021-09-18
Recently, Bristol-Myers Squibb and Merck reported their GPR40 agonist research focused on the modification of α,β-position of phenylpropionic AM 281 derivatives. For example, in recent published patent applications, Bristol-Myers Squibb claimed the pyrrolidine and dihydropyrazole GPR40 agonists wit
-
Our previous study had shown
2021-09-18
Our previous study had shown that silencing FFAR1 expression weakened the action of PIO in increasing insulin secretion in lipotoxic β Cyclopiazonic acid [6]. Resent research found that PIO promoted insulin secretion by upregulating FFAR1 [17]. Therefore, we presumed that FFAR1 may be involved in t
-
Thus aldolase catalyzing the reversible reaction of
2021-09-18
Thus, aldolase catalyzing the reversible reaction of F1,6-P2 synthesis is involved in the formation of the glyconeogenic or glycolytic complex, dependently on the physiological state of the cell. In the process of glycogen synthesis, the enzyme not only supplies the substrate for FBPase and desensit
-
The feasibility of using the Fas Fas
2021-09-18
The feasibility of using the Fas/Fas ligand (FasL) system to target vascular progenitor MM-102 synthesis contributing to intimal hyperplasia has been shown in many studies [[18], [19], [20], [21], [22], [23], [24]]. Fas receptor, a member of tissue necrosis factor family, is a death receptor that in
-
Introduction RNA splicing occurs in the nucleus
2021-09-18
Introduction RNA splicing occurs in the nucleus when noncoding sequences (introns) are removed from the pre-mRNA transcript and coding sequences (exons) are joined to form a mature mRNA [1,2]. This reaction is catalyzed by a multiprotein complex called spliceosome. The spliceosome consists of five
-
br Declarations of interest br
2021-09-18
Declarations of interest Founding information This work was partially supported by the New Energy and Industrial Technology Development Organization (NEDO) Japan [grant number P03043]; and Grants-in-Aid for Scientific Research [grant number 16H00738 to H.M.] from the Japan Society for the Prom
-
Combination inhibitors of FAAH TRPV
2021-09-18
Combination inhibitors of FAAH, TRPV1, and/or COX2 may have the advantage of effective pain relief with a high therapeutic index. For example, arachidonoyl serotonin (AA-5-HT) inhibits both FAAH (IC=1–12μM) and TRPV1 (IC=37–270nM against 100nM capsaicin in HEK-293 cells)., In mice, AA-5-HT had great
-
Tyr phosphorylation of AnxA was
2021-09-18
Tyr23 phosphorylation of AnxA2 was first reported to be involved in endocytosis, particularly in the internalisation of the insulin receptor [20]. Phosphorylated Tyr23 seems to be necessary for the stable association of AnxA2 with endosomes, and for their early-stage transport [14]. The role of AnxA
-
br Characterization of quantal exocytosis by amperometry A
2021-09-18
Characterization of quantal exocytosis by amperometry A secretory vesicle experiences four phases during exocytosis: (i) cargo packaging & translocation, (ii) vesicle docking & priming; (iii) fusion pore formation; (iv) fusion pore expansion and cargo secretion (Fig. 1a). The release of monoamine
-
Z-Guggulsterone br Mechanisms of Resistance As with other ca
2021-09-18
Mechanisms of Resistance As with other cancer treatments in development, resistance is a concern with HHIs. Most observations regarding HHI resistance originate from patients with BCC [78]. In the clinic, resistance to vismodegib and sonidegib were observed when used to treat advanced BCC [78], [
-
Further investigation of the effects of
2021-09-18
Further investigation of the effects of this inhibitor on histone acetylation revealed no HAT inhibitory effects at the level of global histone acetylation after 20h of incubation with C646. After 6h of incubation with C646, however, a slight increase in histone H3 acetylation was observed at lysine
-
Multiple subsets of Breg cells in mice
2021-09-18
Multiple subsets of Breg cells in mice have been identified that could suppress the T cell-mediated response. However, a lack of consensus surface markers for Breg cells made it difficult to judge whether Breg cells are a special B cell subset or whether all Sobetirome australia have an immuno-regu
-
br Materials and methods br Results br Discussion Accurate H
2021-09-18
Materials and methods Results Discussion Accurate HER2 assessment for patients with invasive breast cancer is crucial to determining which patients may benefit from HER2-targeted therapy. The most recent ASCO/CAP guidelines have again redefined HER2 gene amplification as determined by dual-
-
Recently it has been found that treatment of
2021-09-18
Recently, it has been found that treatment of human phagocytic Alsterpaullone sale or microvascular endothelial cells with NO donors inhibited the O2− generating capacity of NADPH oxidase [[8], [9], [10], [11]], which may involve down-regulation or S‑nitrosylation of the p47phox subunit (a cytosolic
-
Using embelin and its analogs as surrogate GPR agonists
2021-09-17
Using embelin and its analogs as surrogate GPR84 agonists we discovered that GPR84 couples to G12 and G13 signaling pathways in addition to Gi, linking receptor function to Rho/Rac signaling and modulation of the cytoskeleton. In primary human macrophages, GPR84 activation leads to Gβγ signaling, Er
13930 records 538/929 page Previous Next First page 上5页 536537538539540 下5页 Last page